-+ 0.00%
-+ 0.00%
-+ 0.00%

Evercore ISI Group Downgrades Legend Biotech to In-Line, Announces $20 Price Target

Benzinga·11/16/2026 13:32:07
Evercore ISI Group analyst Umer Raffat downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to In-Line and announces $20 price target.